University of Ioannina

About: University of Ioannina is a education organization based out in Ioannina, Greece. It is known for research contribution in the topics: Population & Large Hadron Collider. The organization has 7654 authors who have published 20594 publications receiving 671560 citations. The organization is also known as: Panepistimio Ioanninon.

Orlistat-associated adverse effects and drug interactions: a critical review.

Abstract: Orlistat, an anti-obesity drug, is a potent and specific inhibitor of intestinal lipases In light of the recent US FDA approval of the over-the-counter sale of orlistat (60 mg three times daily), clinicians need to be aware that its use may be associated with less well known, but sometimes clinically relevant, adverse effects More specifically, the use of orlistat has been associated with several mild-to-moderate gastrointestinal adverse effects, such as oily stools, diarrhoea, abdominal pain and faecal spotting A few cases of serious hepatic adverse effects (cholelithiasis, cholostatic hepatitis and subacute liver failure) have been reported However, the effects of orlistat on non-alcoholic fatty liver disease are beneficial Orlistat-induced weight loss seems to have beneficial effects on blood pressure No effect has been observed on calcium, phosphorus, magnesium, iron, copper or zinc balance or on bone biomarkers Interestingly, the use of orlistat has been associated with rare cases of acute kidney injury, possibly due to the increased fat malabsorption resulting from the inhibition of pancreatic and gastric lipase by orlistat, leading to the formation of soaps with calcium and resulting in increased free oxalate absorption and enteric hyperoxaluria Orlistat has a beneficial effect on carbohydrate metabolism No significant effect on cancer risk has been reported with orlistat Orlistat interferes with the absorption of many drugs (such as warfarin, amiodarone, ciclosporin and thyroxine as well as fat-soluble vitamins), affecting their bioavailability and effectiveness This review considers orlistat-related adverse effects and drug interactions The clinical relevance and pathogenesis of these effects is also discussed

A Greedy EM Algorithm for Gaussian Mixture Learning

Abstract: Learning a Gaussian mixture with a local algorithm like EM can be difficult because (i) the true number of mixing components is usually unknown, (ii) there is no generally accepted method for parameter initialization, and (iii) the algorithm can get trapped in one of the many local maxima of the likelihood function. In this paper we propose a greedy algorithm for learning a Gaussian mixture which tries to overcome these limitations. In particular, starting with a single component and adding components sequentially until a maximum number k, the algorithm is capable of achieving solutions superior to EM with k components in terms of the likelihood of a test set. The algorithm is based on recent theoretical results on incremental mixture density estimation, and uses a combination of global and local search each time a new component is added to the mixture.

Charged-particle nuclear modification factors in PbPb and pPb collisions at √sNN=5.02 TeV

Abstract: we acknowledge the enduring support for the construction and operation of the LHC and the CMS detector provided by the following funding agencies: BMWFW and FWF (Austria); FNRS and FWO (Belgium); CNPq, CAPES, FAPERJ, and FAPESP (Brazil); MES (Bulgaria); CERN; CAS, MoST, and NSFC (China); COLCIENCIAS (Colombia); MSES and CSF (Croatia); RPF (Cyprus); SENESCYT (Ecuador); MoER, ERC IUT and ERDF (Estonia); Academy of Finland, MEC, and HIP (Finland); CEA and CNRS/IN2P3 (France); BMBF, DFG, and HGF (Germany); GSRT (Greece); OTKA and NIH (Hungary); DAE and DST (India); IPM (Iran); SFI (Ireland); INFN (Italy); MSIP and NRF (Republic of Korea); LAS (Lithuania); MOE and UM (Malaysia); BUAP, CINVESTAV, CONACYT, LNS, SEP, and UASLP-FAI (Mexico); MBIE (New Zealand); PAEC (Pakistan); MSHE and NSC (Poland); FCT (Portugal); JINR (Dubna); MON, RosAtom, RAS and RFBR (Russia); MESTD (Serbia); SEIDI and CPAN (Spain); Swiss Funding Agencies (Switzerland); MST (Taipei); ThEPCenter, IPST, STAR and NSTDA (Thailand); TUBITAK and TAEK (Turkey); NASU and SFFR (Ukraine); STFC (United Kingdom); DOE and NSF (U.S.A.).